Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: Present and future applications

Drugs and Aging

Volumn 24, Issue 7, 2007, Pages 581-602

  Booth, Blake A ^a   Denham, Lori Vidal ^b   Bouhanik, Saadallah ^a   Jacob, Jean T ^a,c   Hill, James M ^a,c,d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d LSU EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; LIPOSOME; MICROSPHERE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

AUSTRALIA; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; DEVICE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; GROUPS BY AGE; HUMAN; IN VITRO STUDY; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULOPATHY; REVIEW; SUSTAINED DRUG RELEASE; ULTRASOUND; UNITED STATES; UVEITIS;

ADULT; AGE FACTORS; AGED; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MACULAR DEGENERATION; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 34547594836     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724070-00006     Document Type: Review

References (145)

1. Sultana Y, Jain R, Aqil M, et al. Review of ocular drug delivery. Curr Drug Deliv 2006 Apr; 3 (2): 207-17
2. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006 Mar; 3 (2): 275-87
3. Mainardes RM, Urban MC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005 May; 6 (3): 363-71
4. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005 Dec 13; 57 (14): 2063-79
5. Lu M, Adamis AP. Ocular delivery of angiostatic agents. Int Ophthalmol Clin 2004; 44 (3): 41-51
6. Yasukawa T, Ogura Y, Tabata Y, et al. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004; 23: 253-81
7. Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Curr Opin Mol Ther 2004 Apr; 6 (2): 195-205
8. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003 Feb; 3 (1): 45-56
9. Kurz D, Ciulla TA. Novel approaches for retinal drug delivery. Ophthalmol Clin North Am 2002; 15: 405-10
10. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004 Apr; 122 (4): 477-85
11. Gohdes DM, Balamurugan A, Larsen BA, et al. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005 Jul; 2 (3): A17
12. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997 Jan; 104 (1): 7-21
13. Klein R. Diabetic retinopathy. Annu Rev Public Health 1996; 17: 137-58
14. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004 Apr; 122 (4): 552-63
15. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001 Feb; 86 (2): 656-8
16. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006 Jul; 10 (3): 588-612
17. Folkman J. Angiogenesis: an organizing principle for drug discovery. Nature Rev 2007 Apr; 6: 273-86
18. Ryan SJ. Subretinal neovascularization. Trans New Orleans Acad Ophthalmol 1983; 31: 43-52
19. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998 Jun; 105 (6): 998-1003
20. Senger DR, Van De WL, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993 Sep; 12 (3-4): 303-24
21. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997 Sep; 46 (9): 1473-80
22. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999 Jul 9; 285 (5425): 245-8
23. Donaldson MJ, Pulido JS. Treatment of nonexudative (dry) age-related macular degeneration. Curr Opin Ophthalmol 2006 Jun; 17 (3): 267-74
24. Toth CA. Macular degeneration: the latest in current surgical management. Retina 2006 Jul; 26 (6 Suppl.): S21-5
25. Lim JI. Macular degeneration: the latest in current medical management. Retina 2006 Jul; 26 (6 Suppl.): S17-20
26. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999 Oct; 117 (10): 1329-45
27. Comer GM, Ciulla TA, Criswell MH, et al. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004; 21 (15): 967-92
28. Pelzek C, Lim JI. Diabetic macular edema: review and update. Ophthalmol Clin North Am 2002 Dec; 15 (4): 555-63
29. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy: PKC-DRS2 Group. Ophthalmology 2006 Dec; 113 (12): 2221-30
30. Ciulla TA, Walker JD, Fong DS, et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 2004 Jun; 15 (3): 211-20
31. Jonas JB, Spandau UH, Kamppeter BA, et al. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2006 May; 113 (5): 800-4
32. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003; 87: 462-8
33. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003 May; 121 (5): 667-73
34. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004 Mar; 122 (3): 336-40
35. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003 Sep; 121 (9): 1279-82
36. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004 Feb; 122 (2): 218-22
37. Jonas JB, Degenring RF, Kreissig I, et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye 2005 Feb; 19 (2): 163-70
38. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005 Mar; 139 (3): 421-8
39. Slakter JS. Anecortave acetate for treating or preventing choroidal neovascularization. Ophthalmol Clin North Am 2006 Sep; 19 (3): 373-80
40. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006 Jan; 113 (1): 3-13
41. Kim IK, Husain D, Michaud N, et al. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006; 47: 357-63
42. Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 2007 Jan; 104 (2): 967-72
43. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 Dec 30; 351 (27): 2805-16
44. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002 Apr; 22 (2): 143-52
45. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006 Apr; 113 (4): 623-32
46. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2002 Nov; 113 (11): e1-12
47. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006 Nov; 26 (9): 1006-13
48. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004 Feb; 24 (1): 132-8
49. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002 Jun; 43 (6): 1994-2000
50. Strom C, Sander B, Klemp K, et al. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005 Oct; 46 (10): 3855-8
51. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000; 41 (5): 961-4
52. Olsen TW, Edelhauser HF, Lim JI, et al. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser and surgical thinning. Invest Ophthalmol Vis Sci 1995; 36: 1893-903
53. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41: 1181-5
54. Cruysberg LP, Nuijts RM, Geroski DH, et al. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther 2002 Dec; 18 (6): 559-69
55. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000 Apr; 41 (5): 1186-91
56. Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior subtenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial. Eur J Ophthalmol 2005 Nov; 15 (6): 746-50
57. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2006 Mar; 82 (3): 479-87
58. Voigt M, Kralinger M, Kieselbach G, et al. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophresis administration. Invest Ophthalmol Vis Sci 2002; 43: 3299-306
59. Behar-Cohen FF, Parel J-M, Pouliquen Y, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res 1997; 65: 533-45
60. Behar-Cohen F, Savoldelli M, Parel JM, et al. Reduction of corneal edema in endotoxin-induced-uveitis after application of L-NAME as nitric oxide synthase inhibitor in rats by iontophoresis. Invest Ophthalmol Vis Sci 1998; 39: 897-904
61. Yokoyama A, Oshitari T, Negishi H, et al. Protection of retinal ganglion cells from ischemia-reperfusion injury by electrically applied Hsp27. Invest Ophthalmol Vis Sci 2001 Dec; 42 (13): 3283-6
62. Oshima Y, Sakamoto T, Yamanaka I, et al. Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther 1998; 5: 1347-54
63. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 2000 Mar; 19 (2): 131-47
64. Langer R. New methods of drug delivery. Science 1990; 249: 1527-33
65. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 2001 May; 215 (3): 143-55
66. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant: the Ganciclovir Implant Study Group. N Engl J Med 1997 Jul 10; 337 (2): 83-90
67. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992 Feb; 110 (2): 188-95
68. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998 Jan; 116 (1): 69-77
69. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006 Jun; 113 (6): 1020-7
70. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000; 20 (4): 402-3
71. Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 1998 Jan; 105 (1): 46-56
72. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999 Mar; 127 (3): 288-93
73. Okabe K, Kimura H, Okabe J, et al. Intraocular tissue distribution of betamethasone after intrascleral administration using a nonbiodegradable drug delivery device. Invest Ophthalmol Vis Sci 2003; 44: 2702-7
74. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001 Aug; 17 (4): 393-401
75. Kato A, Kimura H, Okabe K, et al. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004; 45: 238-44
76. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol 2003 Aug; 87 (8): 1032-7
77. Beeley NR, Stewart JM, Tano R, et al. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J Biomed Mater Res A 2006 Mar 15; 76 (4): 690-8
78. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006 Mar 7; 103 (10): 3896-901
79. Hincal AA, Calis S. Microsphere preparation by solvent evaporation method. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, 2000: 329-43
80. Suggs LJ, Mikos AG. Synthetic biodegradable polymers for medical applications. In: Mark JE, editor. Physical properties of polymers. Woodbury (NY): American Institute of Physics, 1996: 615-24
81. Yasukawa T, Kimura H, Kunou N, et al. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 2000 Feb; 238 (2): 186-90
82. Hashizoe M, Ogura Y, Kimura H, et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol 1994 Oct; 112 (10): 1380-4
83. Hashizoe M, Ogura Y, Takanashi T, et al. Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr Eye Res 1995 Jun; 14 (6): 473-7
84. Hashizoe M, Ogura Y, Takanashi T, et al. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res 1997 Jul; 16 (7): 633-9
85. Kimura H, Ogura Y, Hashizoe M, et al. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 1994 May; 35 (6): 2815-9
86. Miyamoto H, Ogura Y, Hashizoe M, et al. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr Eye Res 1997 Sep; 16 (9): 930-5
87. Morita Y, Ohtori A, Kimura M, et al. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol Pharm Bull 1998 Feb; 21 (2): 188-90
88. Tan DT, Chee SP, Lim L, et al. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 2001 Dec; 108 (12): 2172-81
89. Zhou T, Lewis H, Foster RE, et al. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release 1998 Nov 13; 55 (2-3): 281-95
90. Yasukawa T, Ogura Y, Sakurai E, et al. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005 Dec 13; 57 (14): 2033-46
91. Kunou N, Ogura Y, Yasukawa T, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000 Aug 10; 68 (2): 263-71
92. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003 May 20; 5: 1-16
93. Okabe J, Kimura H, Kunou N, et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003 Feb; 44 (2): 740-4
94. Fialho SL, Rego MB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res 2006 Jun; 31 (6): 525-34
95. Beeley NR, Rossi JV, Mello-Filho PA, et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A 2005 Jun 15; 73 (4): 437-44
96. Haesslein A, Ueda H, Hacker MC, et al. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers. J Control Release 2006 Aug 28; 114 (2): 251-60
97. Le Visage C, Quaglia F, Dreux M, et al. Novel microparticulate system made of poly(methylidene malonate 2.1.2). Biomaterials 2001 Aug; 22 (16): 2229-38
98. Felt-Baeyens O, Eperon S, Mora P, et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int J Pharm 2006 Sep 28; 322 (1-2): 6-12
99. Allergan Inc. Allergan completes acquisition of Oculex Pharmaceuticals, Inc. Allergan's investigational Posurdex® technology demonstrates improvement in patients with macular edema (swelling of the retina) in phase 2 clinical trial according to data presented at American Academy of Ophthalmology [online]. Available from URL: http://www.shareholder.com/AGN/ReleaseDetail.cfm?. ReleaseID=123213 [Accessed 2006 Nov 30]
100. Haller JA. The Retina Debates 2003: new technology and controversies from the posterior segment: intravitreal steroids in retinal diseases: the steroid device. The Oculex Study. Anaheim (CA): American Academy of Ophthalmology, 2003
101. Li X, Jasti BR. Design of controlled release drug delivery systems. New York: McGraw-Hill, 2006
102. Khoobehi B, Stradtmann MO, Peyman GA, et al. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg 1991 Mar; 22 (3): 175-80
103. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992 Oct; 33 (11): 3125-30
104. Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, et al. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration: encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res 2000 Oct; 17 (10): 1323-8
105. Kimura H, Ogura Y, Moritera T, et al. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr Eye Res 1994 May; 13 (5): 353-60
106. Moritera T, Ogura Y, Yoshimura N, et al. Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Curr Eye Res 1994 Mar; 13 (3): 171-6
107. Ogura Y, Kimura H. Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. Surv Ophthalmol 1995 May; 39 Suppl. 1: S17-24
108. Veloso Jr AA, Zhu Q, Herrero-Vanrell R, et al. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest Ophthalmol Vis Sci 1997 Mar; 38 (3): 665-75
109. Moritera T, Ogura Y, Honda Y, et al. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci 1991 May; 32 (6): 1785-90
110. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001 Oct 31; 52 (1): 5-16
111. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003 Aug; 44 (8): 3562-9
112. Sakurai E, Ozeki H, Kunou N, et al. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2001 Jan; 33 (1): 31-6
113. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci 1993 Aug; 34 (9): 2743-51
114. Peyman GA, Conway M, Khoobehi B, et al. Clearance of microsphere- entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int Ophthalmol 1992 Mar; 16 (2): 109-13
115. Moshfeghi AA, Peyman GA. Micro- and nanoparticulates. Adv Drug Deliv Rev 2005 Dec 13; 57 (14): 2047-52
116. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005 Mar 28; 511 (2-3): 191-8
117. Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-coglycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003 Jan; 44 (1): 290-9
118. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003 Mar; 44 (3): 1192-201
119. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003 Nov; 44 (11): 4989-93
120. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003 Jan 5; 458 (3): 283-9
121. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 2004 Oct; 21 (10): 1797-804
122. Mantipragada SB, Horvath LI, Arias HR, et al. Lipid-protein interactions and effect of local anesthetics in acetylcholine receptor-rich membranes from Torpedo marmorata electric organ. Biochemistry 2003 Aug 5; 42 (30): 9167-75
123. Peyman GA, Charles HC, Liu KR, et al. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol 1988; 12 (3): 175-82
124. Cheng L, Hostetler KY, Chaidhawangul S, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci 2000 May; 41 (6): 1523-32
125. Mitra AK, editor. Ophthalmic drug delivery systems. New York (NY): Marcel Dekker, Inc., 2002
126. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002 Jan; 43 (1): 253-9
127. Feinstein SB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol 2004 Aug; 287 (2): H450-7
128. Porter TR, Cwajg JM. Contrast echocardiography. In: Prohost GM, editor. Imaging in cardiovascular disease. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 85-96
129. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol 1968 Sep; 3 (5): 356-66
130. Bekeredjian R, Katus HA, Kuecherer HF. Therapeutic use of ultrasound targeted microbubble destruction: a review of noncardiac applications. Ultraschall Med 2006 Apr; 27 (2): 134-40
131. Schutt EG, Klein DH, Mattrey RM, et al. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals. Angew Chem Int Ed Engl 2003 Jul 21; 42 (28): 3218-35
132. Dijkmans PA, Juffermans LJ, Musters RJ, et al. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr 2004 Aug; 5 (4): 245-56
133. Kost J, Leong K, Langer R. Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc Natl Acad Sci U S A 1989 Oct; 86 (20): 7663-6
134. Zderic V, Clark JI, Vaezy S. Drug delivery into the eye with the use of ultrasound. J Ultrasound Med 2004 Oct; 23 (10): 1349-59
135. Huber PE, Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther 2000 Sep; 7 (17): 1516-25
136. Miller DL, Bao S, Gies RA, et al. Ultrasonic enhancement of gene transfection in murine melanoma tumors. Ultrasound Med Biol 1999 Nov; 25 (9): 1425-30
137. Kim HJ, Greenleaf JF, Kinnick RR, et al. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther 1996 Jul 10; 7 (11): 1339-46
138. Tata DB, Dunn F, Tindall DJ. Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem Biophys Res Commun 1997 May 8; 234 (1): 64-7
139. Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 1997; 23 (6): 953-9
140. Mukherjee D, Wong J, Griffin B, et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol 2000 May; 35 (6): 1678-86
141. Bekeredjian R, Grayburn PA, Shohet RV. Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine. J Am Coll Cardiol 2005 Feb 1; 45 (3): 329-35
142. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol 2006 Mar; 41 (3): 354-62
143. Church CC. The effects of an elastic solid surface layer on the radial pulsations of gas bubbles. J Acoust Soc Am 1995; 97 (3): 1510-21
144. Hoff L, Sontum PC, Hovem JM. Oscillations of polymeric microbubbles: effect of the encapsulating shell. J Acoust Soc Am 2000 Apr; 107 (4): 2272-80
145. Shankar PM, Krishna PD, Newhouse VL. Subharmonic back-scattering from ultrasound contrast agents. J Acoust Soc Am 1999 Oct; 106 (4 Pt 1): 2104-10